Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia
| Status: | Completed |
|---|---|
| Conditions: | Blood Cancer, Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | Any - 50 |
| Updated: | 4/12/2017 |
| Start Date: | March 2011 |
| End Date: | November 2016 |
Impact of Washed Transfusions in Adult Patients With Acute Myeloid or Lymphoid Leukemia
The purpose of this study is to determine whether a novel standard of care protocol, washing
red cell and platelet transfusions for younger patients with acute leukemia, has yielded
improved clinical outcomes at Strong Memorial Hospital (Rochester, New York, USA). This
standard of care was implemented based upon an earlier randomized trial (BMC Blood
Disorders. 2004 Dec 10;4(1):6) The comparator will be historical controls from the medical
literature.
red cell and platelet transfusions for younger patients with acute leukemia, has yielded
improved clinical outcomes at Strong Memorial Hospital (Rochester, New York, USA). This
standard of care was implemented based upon an earlier randomized trial (BMC Blood
Disorders. 2004 Dec 10;4(1):6) The comparator will be historical controls from the medical
literature.
The purpose of this study is to determine whether a novel standard of care protocol, washing
red cell and platelet transfusions for younger patients with acute leukemia, has yielded
improved clinical outcomes at Strong Memorial Hospital (Rochester, New York, USA). This
standard of care was implemented based upon an earlier randomized trial (BMC Blood
Disorders. 2004 Dec 10;4(1):6) The comparator will be historical controls from the medical
literature. Key outcomes will be treatment related mortality (deaths at 30, 60 and 100 days)
and three year survival.
red cell and platelet transfusions for younger patients with acute leukemia, has yielded
improved clinical outcomes at Strong Memorial Hospital (Rochester, New York, USA). This
standard of care was implemented based upon an earlier randomized trial (BMC Blood
Disorders. 2004 Dec 10;4(1):6) The comparator will be historical controls from the medical
literature. Key outcomes will be treatment related mortality (deaths at 30, 60 and 100 days)
and three year survival.
Inclusion Criteria:
- previously untreated patients with a diagnosis of acute leukemia between the ages of
0 and 50 (AML) and 18 and 50 (ALL)
Exclusion Criteria:
- all other patients
We found this trial at
1
site
Click here to add this to my saved trials
